Sulfadiazine

PUT YOUR IDEALS INTO PRACTICE: VOLUNTEERING WITH DOCTORS WITHOUT BORDERS Fontainebleau B Tuesday, November 9, 2004 12: Doctors Without Borders Mdecins Sans Frontires MSF ; urgently needs physicians for field projects. Join David Olson, MD, medical advisor to MSF-USA, and other representatives from the organization for a discussion on volunteer opportunities in the field. CHAIR D. Olson. The present study evaluated in vitro and in vivo a new chlorhexidine C ; -silver sulfadiazine S ; vascular catheter the CS2 catheter ; characterized by a higher C content and by the extended release of the surfacebound antimicrobials. The CS2 catheter was compared with a first-generation, commercially available CS catheter the CS1 catheter ; . The CS2 catheter produced slightly smaller zones of inhibition mean difference, 0.9 mm [P 0.001] ; at 24 h against Staphylococcus aureus and five other microorganisms by several different methodologies. However, in a rabbit model, both CS catheters were similarly efficacious in preventing a catheter infection when the rabbits were inoculated with 104 to 107 CFU of S. aureus at the time of catheter insertion. The CS2 catheter retained its antimicrobial activity significantly longer in vitro and in vivo half-lifes exceeded 34 and 7 days, respectively ; and was also significantly more efficacious in preventing a catheter infection when 106 CFU of S. aureus was inoculated 2 days after catheter implantation P 0.001 ; . These results suggest that prolonged anti-infective activity on the external catheter surface provides improved efficacy in the prevention of infection. Vascular catheters coated with antiseptic or antimicrobial agents have been shown to significantly reduce the risk of catheter-related bloodstream infection 6, 8, 14 ; , which is an important cause of morbidity and mortality, with a significant economic burden 10 ; . Vascular catheters impregnated with chlorhexidine C ; and silver sulfadiazine S ; CS1 catheters ; were efficacious in preventing catheter-related bloodstream infections in a large randomized clinical trial 6 ; , and their efficacy has been demonstrated in a meta-analysis 14 ; for patients with a mean duration of catheterization of less than 12 days. However, other studies, and in particular, another large randomized trial 5 ; with patients with a mean duration of catheterization of 20 days, found no benefit in the use of CS1 catheters, raising the possibility that the anti-infective protection offered by these catheters lasts only for a relatively short period of time about 10 days ; . The present study evaluated whether a new catheter with increased C content and extended release of the surface-bound antimicrobials the CS2 catheter ; has improved anti-infective properties. Part of this work was presented at the 37th Annual Meeting of the Infectious Diseases Society of America, 18 to 21 November 1999, Philadelphia, Pa., abstr. 465.

Ent time there is no information on whether sulfadiazine therapy has any effect on caries in humans. As with penicillin, the concentrations examined were those expected to occur in the salivas of treated subjects. MATERIALS AND METHODS Microorganisms. Type strains ofS. mutans tested included OMZ-61 serotype a ; , BHT serotype b ; , JC2, Ingbritt serotype c ; , SL-1, 6715 serotype d ; , and LM-7 serotype e ; 2, 13, 14 ; . Fresh isolates were obtained from children who were untreated siblings of outpatients at the Toronto Hospital for Sick Children. Selection of concentrations of antimicrobial agents. The antimicrobial agents were tested at a range of concentrations chosen to include those expected to occur in saliva. Since previous workers studying the effect of long-term penicillin therapy on caries 8, 9 ; did not report the salivary penicillin levels in their subjects, it was necessary to estimate the levels from other information in the literature. The oral administration of 200, 000 U of penicillin G has been shown to result in a serum level of approximately 0.12 jug ml 11 ; . Inasmuch as salivary penicillin levels are approximately 1% of serum levels 1 ; , we estimated the maximum salivary concentration from 200, 000 U of penicillin G to be between 1 and 2 ng ml. The concentrations tested ranged from 0.5 to 48 ng ml. The sulfadiazine concentrations tested, 1 and 10 itg ml, were both within the range of reported salivary excretion levels 3, 17 ; . Effects of penicillin and sulfadiazine on the growth of S. mutans. Inocula were prepared by growing S. mutans strains for 24 h in Mueller-Hinton broth Difco Laboratories, Detroit, Mich. ; sup.
Saccharomyces lomofungin treatment, 716, 723 Saccharomyces cerevisiae nalidixic acid effect on, 562 thiolutin treatment, 729 Salmonella typhoda endotoxin synergistic toxicity, 686 endotoxin toxicity, 599 Sch 13706 comparison with other aminoglycosides, 87 Sewage drug resistance of coliforms in, 175 Silver sulfadiazine P. aeruginosa, 621 Sisomicin comparison with gentamicin and tobramycin, 24, 87 Spectinomycin activity against Enterobacteriaceae and Pseudomonas, 338 in vitro effect on N. gonorrhoeae, 335 Spiramycin distribution in serum and milk, 607 Sporotrichosis therapy with 5-fluorocytosine, 95 and sulfasalazine. Continue the Taking Charge of Your Heart Health program for CAD including educating physicians on the program, publicizing it to members and targeting members identified through administrative data. Continue implementation of the QMed TM program for members at high risk for CAD including ongoing education to physicians. Continue provider-specific reporting for patients diagnosed with CAD who do not have administrative data that they have received prescriptions for beta-blockers. Identify members with CAD that have been recently discharged from the hospital and encourage physicians to screen these members for eligibility in our disease management programs for CAD as well as for smoking and depression. Continue education to the CAD members regarding programs available to them that target related conditions and barriers e.g. Pharmacy discount, StopSmoking SM, and depression programs.
Please visit mercyhealthplans for a listing of prior authorization precertification ; requirements by cpt code and sulfinpyrazone. Argentina: Nadia Felix, CST, MPsy Phone: 54 11 4803 E-mail: nadiafelix fibertel .ar Australia: Susie Spratt Phone: 61 7 4638 E-mail: holisticlife bigpond Austria: Marianne Schauperl, CST-D Phone: 43 316 840 E-mail: office upledger Belgium: Marc van der Straeten, DO, CST-D Phone: 32 3 297 E-mail: info upledger.be Brazil: Jussara De Avellar Serpa Phone: 55 21 2431 E-mail: jserpa rjnet Czech Republic: Stanislav Zapletal Phone: 42 05 7333 E-mail: zapletal seznam.cz Germany: Gert Groot Landeweer, CST-D Phone: 49 761 37353 E-mail: upledger t-online Hong Kong: Alice Kit-Ping Tsang Lau Phone: 852 9028 3096 E-mail: elite re2004 yahoo Iceland: Birgir Hilmarsson, MT Phone: 354 466 3090 E-mail: birgir upledger Erla Olafsdottir, PT Phone: 354 466 3090 E-mail: erla upledger Ireland: Mike & Heath Wilson Phone: 353 65 708 E-mail: craniosacral upledgerireland Israel: Gadi Nelinger, AppSci, BPT Phone: 972 3 522 E-mail: post upledger Italy: A.J. de Koning, DO, CST-D Phone: 39 040 452 E-mail: upledger tin Italy: Diego Maggio, DO, CST-D Phone: 39 040 347 E-mail: dm.upledger mail Japan: Koichi Hiratsuka, MRO J ; Phone: 81 3 5940 E-mail: info ui-japan Mexico: Monica Gerez-Fernandez Phone: 52 55 E-mail: monicagerez hotmail Margarita Soberon Phone: 52 55 56 E-mail: msobernon att .mx Netherlands: Annick Smit-Pino, PT Phone: 31 343 514031 E-mail: info upledger.nl Panama: Roberto Eisenmann Phone: 507 269 3000 E-mail: empeisen empeisen Portugal: Jose Campos, DO, BSc Phone: 351 21 453 E-mail: jose mpos netcabo.pt Russia: Konstantin Charapov Phone: 7 812 970 E-mail: charapov list Scandinavia: Gusti Axelsson, MT, CST Phone: 45 5782 2077 E-mail: post upledger Singapore: Kheng Chua Phone: 65 6258 5031 E-mail: kheng greenpartners .sg South Africa: John Page, DO, CST-D Phone: 441738 444404 E-mail: mail upledger Spain: Jose Luis Perez Batlle, DO Phone: 34 958 5204 E-mail: cob valnet Switzerland: Matthias Moesle, CST-D Phone: 41 91 780 E-mail: mail upledger.ch United Kingdom: John Page, DO, CST-D Phone: 44 1738 444404 E-mail: mail upledger.

Results of Table 3 showed that myoglobin titers were consistently higher in autoimmune disease patients in comparison to the controls. The average myoglobin level in autoimmune disease patients was 3.3 X than in the controls, derived by average titer of autoimmune disease divided by average titer of controls. Table 4. ELISA Titer 100 l for Insulin in saliva of normal people and patients with autoimmune disease Controls normal 1 2 3 Average ELISA titer 100l 450 600 Diabetes patients 1A 2A 3A Average ELISA titer 100l 1800. Representing an international Executive Search and Human Capital Consulting firm, Morgan & Banks Middle East, based in Dubai, United Arab Emirates, our Middle East regional office we are searching for the newly created roles of Chief Medical Officer CMO ; and Chief Operating Officer COO ; for a Sports Medicine and Orthopaedic Hospital to be based in Doha in the State of Qatar and believe that this role may be of some interest to you. If you are interested please send us an up-to-date copy of your CV. We are looking forward to discussing the values of this role with you. Should you have any questions, please don't hesitate to contact us. Contact person: Mr. Will McAlpine, Researcher, Morgan & Banks Middle East, PO Box 35499, Dubai, United Arab Emirates Tel: 00971 4 282 Fax: 00971 4 282 Website: : morganbanksme and surmontil.

J Pharm Pharmaceut Sci ualberta ~csps ; 6 2 ; : 101-188, 2003 presented at the AAPS meeting in Toronto November 2002 ; . 75. STABILIZATION OF NANOPARTICULATE DISPERSIONS USING PROTEINS AS SURFACE STABILIZERS Christian Wertz, Elan Drug Delivery, Inc., King of Prussia, Pennsylvania, USA Purpose. To investigate the use of surface-active proteins as surface stabilizers in nanoparticulate dispersions and to compare the bioadhesive nature of these formulations to traditional dispersions formulated with polymeric stabilizers. Methods. High-energy milling studies were conducted using various drug naproxen, nimesulide, and itraconazole ; and protein fibrinogen, -globulin, albumin, casein, and lysozyme ; combinations. Resulting dispersions were characterized using particle size analysis, microscopy, and electrophoresis. Using barium sulfate as a model drug, a stable drug protein lysozyme ; dispersion was then compared to a traditional drug polymer HPCSL ; dispersion using a suitable bioadhesion assay to determine the extent of nanoparticulate adhesion to mucin substrates. Results. Stable nanoparticulate dispersions were generated only when lysozyme was used as the surface stabilizer. Formulations using other proteins resulted in severely aggregated, unstable systems. Electrophoresis measurements on the stable lysozyme formulations revealed large, positive zeta potentials, indicating the importance of electrostatic repulsion in these systems. The positive charge associated with lysozyme was also responsible for the strong adhesion of the nanoparticles to the negatively charged mucin layers, resulting in enhanced bioadhesion when compared to uncharged polymer systems. Conclusions. Due to its relatively compact size, structural stability, and high isoelectric point, lysozyme proved a suitable surface stabilizer in the formulation of stable nanoparticulate dispersions while proteins with different physical and structural characteristics performed poorly. These characteristics also resulted in improved bioadhesion of the nanoparticulate dispersions, making lysozyme an ideal surface stabilizer for the delivery of poorly soluble drugs having low bioavailabilities. 76. WOUND HEALING ACTIVITY OF HIALURONIC ACID FROM UMBILICAL CORD Loida Orua Sanchez, Gabriel Coto, Lic. Guillermo Lago Histoterapia Placentaria Center; Regulatory Authorities of Quality Control of the Drug The hyaluronic acid HA ; is a glucosaminoglycans present in the connective tissue of all body and have very terapeutical effect. Purpose. A HA crude extracted from the umbilical cord of human placentae was pharmacologically assessed as healing jelly. Methods. The experimental design used 20 Spraguey Dawley adult rats as biological model. The environmental conditions such as air exchange cycles, room temperature, relative humidity and light cycle were controlled throughout the experiment. Four wounds were made in the dorsum to each animal using disposable cutaneous biotomes of 9 mm. Treatments applied were: control spontaneous C ; , placebo P ; , silver sulfadiazine SS ; and HA at 4%. Animals were treated for 7 days and there was a daily clinical control of the wounds. The samples of ten animal was processed for histophatology stained with hematoxilin eosin and Massons trichrome for evaluate the dermal reconstitution and epithelial migration. The samples of the other animal were used for a morphometric study of all measurements through an imagen processing software Digipat System, EICISOFT. Cuba ; , was determined the percentage of total re-epithelized area, the epithelial linear growth, the wound perimeter and circularity factor. Results. The product evaluated HA showed a better response regarding the remaining treatments with the healing of 70% of the wounds in the epithelial migration. Also it controlled the dermal reconstitution by 50% in the II degree and by 20% in the III degree demonstrating a matrix with collagenous fibres more mature than the rest. In the planimetry study this treatment was also of best evolution with 89.33% of re-epithelialized area, a shorter wound perimeter with 10.32 mm and larger lineal growth with 5.5 mm and a circularity lower than 61.33 for p 0.05 ; . this results are similar a the literature publicate. Conclusion. The hyaluronic acid jelly at 4% is a medication that contributes to accelerate the wound healing of the biomodel essayed. Key words: re-epittelization, dermal reconstitutions, hialuronic acid, wound healing.